Neuronetics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $218.5M
- Price
- $3.14
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 240.0K
About
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Quick stats
Shares outstanding69.6M
Computed float34.2M
Float / shares49.1%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001227636
Websitehttps://www.neurostar.com
AI Summary
AI-generated1/21
majorbullishearnings
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Neuronetics reported Q2 revenue of $41.6 million, up 9.1% year-over-year, driven primarily by a 16.8% increase in Greenbrook clinic revenue to $26.9 million.
The company achieved a significant operational milestone, flipping Adjusted EBITDA to positive $0.3 million compared to a loss of $5.6 million in the prior year, while the net loss narrowed to $3.4 million.
Neuronetics reaffirmed its full-year 2026 revenue guidance of $160 million to $164 million and tightened its operating expense outlook to a range of $95 million to $100 million.
Leadership changes included the appointment of Nir Naor as CFO and the promotion of Cory Anderson to lead the Greenbrook business unit.
Red flags
- Total cash balance decreased to $25 million from $34.1 million at year-end 2025
- Company continues to report GAAP net losses and negative cash flow from operations